NCT00004263View on ClinicalTrials.gov

Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 31, 1999

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions
LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

7-hydroxystaurosporine (UCN-01)

20 mg/m2 IV over 24 hours on days 2-4 of course 1 and over 36 hours beginning on day 2 of subsequent courses. Treatment repeats every 4 weeks for a maximum of 4 courses.

DRUG

Cytarabine (Ara-C)

Starting dose 1 g/m2 IV over 24 hours on days 1-4 of each course. Treatment repeats every 4 weeks for a maximum of 4 courses.

Trial Locations (2)

43210

Arthur G. James Cancer Hospital - Ohio State University, Columbus

77030

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00004263 - Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter